Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Capital Expenditures (2018 - 2025)

Organogenesis Holdings (ORGO) has 8 years of Capital Expenditures data on record, last reported at $4.7 million in Q4 2025.

  • For Q4 2025, Capital Expenditures rose 38.41% year-over-year to $4.7 million; the TTM value through Dec 2025 reached $14.2 million, up 41.06%, while the annual FY2025 figure was $14.2 million, 41.06% up from the prior year.
  • Capital Expenditures reached $4.7 million in Q4 2025 per ORGO's latest filing, up from $2.2 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $21.6 million in Q3 2021 and bottomed at -$22.2 million in Q4 2021.
  • Average Capital Expenditures over 5 years is $4.3 million, with a median of $4.0 million recorded in 2024.
  • Peak YoY movement for Capital Expenditures: tumbled 125.38% in 2021, then soared 6051.59% in 2023.
  • A 5-year view of Capital Expenditures shows it stood at -$22.2 million in 2021, then skyrocketed by 147.91% to $10.7 million in 2022, then tumbled by 68.81% to $3.3 million in 2023, then rose by 1.11% to $3.4 million in 2024, then soared by 38.41% to $4.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were $4.7 million in Q4 2025, $2.2 million in Q3 2025, and $7.1 million in Q2 2025.